Basic Information
INFLUVAC TETRA, SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE 0.5 ML
INJECTION, SUSPENSION
Regulatory Information
SIN15591P
December 4, 2018
Prescription Only
Therapeutic
SUBCUTANEOUS, INTRAMUSCULAR
August 10, 2023
May 30, 2025
XJ07BB02
Company Information
ABBOTT LABORATORIES (SINGAPORE ) PRIVATE LIMITED
ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED
Active Ingredients
Strength: 15 micrograms HA/0.5ml
Strength: 15 micrograms HA/0.5ml
Strength: 15 micrograms HA/0.5ml
Strength: 15 micrograms HA/0.5ml
Detailed Information
Contraindications
**4.3. Contraindications** Hypersensitivity to the active substances, to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ or to any component that may be present as traces such as eggs (ovalbumin, chicken proteins), formaldehyde, cetyltrimethylammonium bromide, polysorbate 80 or gentamicin. Immunization shall be postponed in patients with febrile illness or acute infection.
Indication Information
**4.1. Therapeutic indications** Prophylaxis of influenza, especially those who run an increased risk of associated complications. Influvac® Tetra is indicated in adults and children from 6 months of age. The use of Influvac® Tetra should be based on official recommendations.